Grade 3 or above irAE occurred in 6.0% patients in the socazolimab plus EC group and 0.8% patients in the placebo plus EC group, with alanine aminotransferase increased (1.2%) in the socazolimab plus EC group and pneumonia (0.8%) most commonly seen in the placebo plus EC group were the most (Supplementary Table 3). This evidence concerns the gene GPT and pneumonia.